WCK 5222 (cefepime-zidebactam, 2 g + 1g, every 8 h [q8h]) is in clinical development for the treatment of infections caused by carbapenem-resistant and multidrug-resistant (MDR) Gram-negative bacilli. We determined the in vitro susceptibility of 1,385 clinical isolates of non-carbapenem-susceptible Enterobacterales , MDR Pseudomonas aeruginosa (also non-carbapenem susceptible), Stenotrophomonas maltophilia , and Burkholderia spp.
No takes yet. Share an insight, caveat, or question.
Karlowsky et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: